146 related articles for article (PubMed ID: 11149723)
21. Oral busulfan pharmacokinetics and engraftment in children with Hurler syndrome and other inherited metabolic storage diseases undergoing hematopoietic cell transplantation.
Jacobson P; Park JJ; DeFor TE; Thrall M; Abel S; Krivit W; Peters C
Bone Marrow Transplant; 2001 Apr; 27(8):855-61. PubMed ID: 11477444
[TBL] [Abstract][Full Text] [Related]
22. Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders.
Hassan M; Fasth A; Gerritsen B; Haraldsson A; Syrůcková Z; van den Berg H; Sandström M; Karlsson M; Kumlien S; Vossen J
Bone Marrow Transplant; 1996 Nov; 18(5):843-50. PubMed ID: 8932835
[TBL] [Abstract][Full Text] [Related]
23. Determination of initial i.v. CYA dosage to achieve target AUC values in pediatric hematopoietic stem cell transplant patients.
Jin M; Seto W; Taylor T; Saunders EF; Doyle J; Dupuis LL
Bone Marrow Transplant; 2008 Oct; 42(7):455-9. PubMed ID: 18622423
[TBL] [Abstract][Full Text] [Related]
24. Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation.
Bartelink IH; Bredius RG; Ververs TT; Raphael MF; van Kesteren C; Bierings M; Rademaker CM; den Hartigh J; Uiterwaal CS; Zwaveling J; Boelens JJ
Biol Blood Marrow Transplant; 2008 Jan; 14(1):88-98. PubMed ID: 18158965
[TBL] [Abstract][Full Text] [Related]
25. Retrospective appraisal of busulfan dose adjustment in children.
Dupuis LL; Najdova M; Saunders EF
Bone Marrow Transplant; 2003 Apr; 31(8):729. PubMed ID: 12692614
[No Abstract] [Full Text] [Related]
26. Intraindividual variability in busulfan pharmacokinetics in patients undergoing a bone marrow transplant: assessment of a test dose and first dose strategy.
Lindley C; Shea T; McCune J; Shord S; Decker J; Harvey D; Petros WP; Garbriel D; Serody J; Kirby S; Wiley J
Anticancer Drugs; 2004 Jun; 15(5):453-9. PubMed ID: 15166618
[TBL] [Abstract][Full Text] [Related]
27. I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients.
Nguyen L; Fuller D; Lennon S; Leger F; Puozzo C
Bone Marrow Transplant; 2004 May; 33(10):979-87. PubMed ID: 15064687
[TBL] [Abstract][Full Text] [Related]
28. Busulphan given as four single daily doses of 150 mg/m2 is safe and effective in children of all ages.
Shaw PJ; Nath C; Berry A; Earl JW
Bone Marrow Transplant; 2004 Aug; 34(3):197-205. PubMed ID: 15195074
[TBL] [Abstract][Full Text] [Related]
29. Busulfan dosing in children with BMIs ≥ 85% undergoing HSCT: a new optimal strategy.
Browning B; Thormann K; Donaldson A; Halverson T; Shinkle M; Kletzel M
Biol Blood Marrow Transplant; 2011 Sep; 17(9):1383-8. PubMed ID: 21288495
[TBL] [Abstract][Full Text] [Related]
30. Risk-adjusted monitoring of veno-occlusive disease following Bayesian individualization of busulfan dosage for bone marrow transplantation in paediatrics.
Brice K; Valerie B; Claire G; Valerie M; Yves B; Gilles A; Nathalie B
Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):135-43. PubMed ID: 17952879
[TBL] [Abstract][Full Text] [Related]
31. High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen.
Geddes M; Kangarloo SB; Naveed F; Quinlan D; Chaudhry MA; Stewart D; Savoie ML; Bahlis NJ; Brown C; Storek J; Andersson BS; Russell JA
Biol Blood Marrow Transplant; 2008 Feb; 14(2):220-8. PubMed ID: 18215782
[TBL] [Abstract][Full Text] [Related]
32. Chronopharmacology of high-dose busulfan in children.
Vassal G; Challine D; Koscielny S; Hartmann O; Deroussent A; Boland I; Valteau-Couanet D; Lemerle J; Lévi F; Gouyette A
Cancer Res; 1993 Apr; 53(7):1534-7. PubMed ID: 8453619
[TBL] [Abstract][Full Text] [Related]
33. Integration of modelling and simulation into the development of intravenous busulfan in paediatrics: an industrial experience.
Nguyen L
Fundam Clin Pharmacol; 2008 Dec; 22(6):599-604. PubMed ID: 19049661
[TBL] [Abstract][Full Text] [Related]
34. Performance of Busulfan Dosing Guidelines for Pediatric Hematopoietic Stem Cell Transplant Conditioning.
Zao JH; Schechter T; Liu WJ; Gerges S; Gassas A; Egeler RM; Grunebaum E; Dupuis LL
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1471-8. PubMed ID: 25977229
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of high-dose i.v. treosulfan in children undergoing treosulfan-based preparative regimen for allogeneic haematopoietic SCT.
Główka FK; Karaźniewicz-Łada M; Grund G; Wróbel T; Wachowiak J
Bone Marrow Transplant; 2008 Oct; 42 Suppl 2():S67-70. PubMed ID: 18978748
[TBL] [Abstract][Full Text] [Related]
36. New insights into the pharmacokinetics of intravenous busulfan in children with sickle cell anemia undergoing bone marrow transplantation.
Gaziev J; Isgrò A; Mozzi AF; Petain A; Nguyen L; Ialongo C; Dinallo V; Sodani P; Marziali M; Andreani M; Testi M; Paciaroni K; Gallucci C; De Angelis G; Alfieri C; Ribersani M; Lucarelli G
Pediatr Blood Cancer; 2015 Apr; 62(4):680-6. PubMed ID: 25557687
[TBL] [Abstract][Full Text] [Related]
37. Home administration of high-dose oral busulfan in patients undergoing hematopoietic stem cell transplantation.
Matthews RH; Emami M; Connaghan DG; Holland HK; Morris LE
Bone Marrow Transplant; 2007 Apr; 39(7):397-400. PubMed ID: 17322933
[TBL] [Abstract][Full Text] [Related]
38. Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens.
Grochow LB
Semin Oncol; 1993 Aug; 20(4 Suppl 4):18-25; quiz 26. PubMed ID: 8342071
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics of liposomal busulphan in man.
Hassan Z; Ljungman P; Ringdén O; Winiarski J; Nilsson C; Aschan J; Whitley HR; Hassan M
Bone Marrow Transplant; 2001 Mar; 27(5):479-85. PubMed ID: 11313681
[TBL] [Abstract][Full Text] [Related]
40. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study.
Vassal G; Deroussent A; Hartmann O; Challine D; Benhamou E; Valteau-Couanet D; Brugières L; Kalifa C; Gouyette A; Lemerle J
Cancer Res; 1990 Oct; 50(19):6203-7. PubMed ID: 2400986
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
